论文部分内容阅读
目的探讨尤瑞克林联合降纤酶对急性脑梗塞患者神经功能缺损及血浆纤维蛋白原的影响。方法 67例急性脑梗塞患者随机分为对照组33例,观察组34例,对照组予尤瑞克林治疗,观察组予尤瑞克林联合降纤酶治疗,比较两组治疗前后神经功能缺损(NIHSS)评分、血浆纤维蛋白原水平,统计临床疗效及不良反应发生率。结果观察组总有效率94.12%高于对照组72.73%(P<0.05);治疗后1、2周、1个月观察组NIHSS评分及血浆纤维蛋白原水平均低于对照组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论尤瑞克林联合降纤酶治疗急性脑梗塞患者疗效显著,可有效改善患者血浆纤维蛋白原水平及神经功能缺损程度,安全性高。
Objective To investigate the effects of uracil combined defibrase on neurological deficits and plasma fibrinogen in patients with acute cerebral infarction. Methods Sixty-seven patients with acute cerebral infarction were randomly divided into control group (n = 33), observation group (n = 34), control group (n = 28) and norepinephrine combined with defibrase. The neurological deficits (NIHSS) score, plasma fibrinogen level, statistical clinical efficacy and incidence of adverse reactions. Results The total effective rate in observation group was 94.12%, which was significantly higher than that in control group (72.73%, P <0.05). NIHSS score and plasma fibrinogen level in observation group at 1, 2 and 1 month after treatment were lower than those in control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The combination therapy of uracil and defibrase can effectively improve the level of fibrinogen and the degree of neurological deficits in patients with acute cerebral infarction. It is safe and safe.